Salakshna Nuntida, Thanasarnaksorn Wilai, Supasiri Thanan
Dr. Thanasarnaksorn is with the Samitivej Esthetics Institute, Samitivej Sukhumvit Hospital, and the Division of Dermatology, Department of Medicine, Faculty of Medicine at Ramathibodi Hospital of Mahidol University in Bangkok, Thailand.
Dr. Salakshna is with the Samitivej Esthetics Institute, Samitivej Chinatown Hospital in Bangkok, Thailand and the Science Division at Mahidol University International College in Nakhon Pathom, Thailand.
J Clin Aesthet Dermatol. 2021 Aug;14(8):57-60. Epub 2021 Aug 1.
Botulinum toxin type A (BTxA) is used for cosmetic procedures, but its use for nasal dorsum augmentation has, to our knowledge, never been studied.
Here, we describe a method for using BTxA injection for nasal dorsum augmentation.
This was a pilot study. Participants aged 20 to 60 years were recruited and injected with BTxA in the upper nasal area with either Xeomin (Merz Pharmaceuticals GmbH, Frankfurt, Germany) or Dysport (Galderma Laboratories, Fort Worth, Texas). The primary outcome measured was the upper nasal area's volume change from baseline, calculated using a Quantificare camera (San Francisco, California). The volumizing effect was subjectively graded by two blinded dermatologists and participants, and pain scores and adverse events were recorded.
Fourteen participants, including two men and 12 women, aged 35.78±9.16 years were recruited. Overall, the volume of the upper nasal area increased after BTxA injection (<0.001). The volume increase immediately and, at one week after injection, presented a statistically significant difference from baseline, with median (interquartile range) volume differences of 0.095mL (0.010-0.205; <0.001) and 0.095mL (0.0475-0.155; <0.001), respectively. Two blinded dermatologists and all participants observed volumizing of the nasal dorsum. The effect appeared to last for one month.
This study suggests that injecting BTxA in the upper nasal area is a convenient, minimally invasive technique with minimal side effects for nasal dorsum augmentation.
A型肉毒杆菌毒素（BTxA）用于美容手术，但据我们所知，其用于鼻背增高的情况从未被研究过。
在此，我们描述一种使用BTxA注射进行鼻背增高的方法。
这是一项试点研究。招募了年龄在20至60岁之间的参与者，并在上鼻区域注射了Xeomin（德国法兰克福默克制药有限公司）或Dysport（美国得克萨斯州沃思堡高德美实验室）的BTxA。测量的主要结果是上鼻区域相对于基线的体积变化，使用Quantificare相机（加利福尼亚州旧金山）进行计算。由两名不知情的皮肤科医生和参与者对增容效果进行主观评分，并记录疼痛评分和不良事件。
招募了14名参与者，包括2名男性和12名女性，年龄为35.78±9.16岁。总体而言，注射BTxA后上鼻区域的体积增加了（<0.001）。注射后立即以及注射后一周时，体积增加与基线相比具有统计学显著差异，中位数（四分位间距）体积差异分别为0.095mL（0.010 - 0.205；<0.001）和0.095mL（0.0475 - 0.155；<0.001）。两名不知情的皮肤科医生和所有参与者均观察到鼻背增容。效果似乎持续了一个月。
本研究表明，在上鼻区域注射BTxA是一种方便、微创且副作用最小的鼻背增高技术。
